MN 553 Advanced Pharmacology Unit 9 Quiz
Question 1 point
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading
to:
Question options:
A need to monitor drugs metabolized by 2D6 for toxicity
Increased dosages needed of drugs metabolized by 2D6, such as the selective
serotonin reuptake inhibitors
Decreased conversion of codeine to morphine by CYP 2D6
The need for lowered dosages of drugs, such as beta blockers
Question 1/1
2 point
Rifampin is a nonspecific CYP450 inducer that may:
Question options:
Lead to toxic levels of rifampin and must be monitored closely
Cause toxic levels of drugs, such as oral contraceptives, when coadministered
Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
failure
Cause nonspecific changes in drug metabolism
Question 1/1
3 point
Inhibition of P-glycoprotein by a drug such as quinidine may
lead to:
Question options:
Decreased therapeutic levels of quinidine
Increased therapeutic levels of quinidine
Decreased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
Increased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
Question 1/1
4 point
Warfarin resistance may be seen in patients with VCORC1
mutation, leading to:
Question options:
Toxic levels of warfarin building up
Decreased response to warfarin
, Increased risk for significant drug interactions with warfarin
Less risk of drug interactions with warfarin
Question 1/1
5 point
Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
Question options:
Erythromycin
Digoxin
Cetuximab
Rifampin
Question 1/1
6 point
Carbamazepine has a Black Box Warning recommending
testing for the HLA-B*1502 allele in patients with Asian
ancestry prior to starting therapy due to:
Question options:
Decreased effectiveness of carbamazepine in treating seizures in Asian patients
with the HLA-B*1502 allele
Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502
Allele
Patients who have the HLA-B*1502 allele being more likely to have a resistance
to carbamazepine
Question 1/1
7 point
A genetic variation in how the metabolite of the cancer drug
irinotecan SN-38 is inactivated by the body may lead to:
Question options:
Decreased effectiveness of irinotecan in the treatment of cancer
Increased adverse drug reactions, such as neutropenia
Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
Increased concerns for irinotecan being carcinogenic
Question 1/1
8 point
A good history of herb and supplement use is critical before
prescribing because approximately ____ % of patients in the
United States are using herbal products.
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller instructor. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $10.49. You're not tied to anything after your purchase.